eli lilly glp-1 news FDA just approved orforglipron (Foundayo), Lilly's oral receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest The massive popularity of GLP-1

Tek and his team

Most improve after a dose reduction which is exactly why slow titration matters

Anti-Aging: Glutathione helps firm skin and reduces wrinkles, promoting a youthful look

ADA: Lilly makes its case for oral GLP-1 orforglipron A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control data in patients with type 2 diabetes, and a side-effect profile free of the liver toxicity that scuppered rival candidates from Pfizer

The Super-Responder Cluster (roughly 22 percent of reports): IGF-1 increase of 60 to 120 percent from pre-cycle baseline labs Lean body mass gain of 2 to 4 kg over 12 weeks (confirmed by DEXA in a minority of cases) Subjective sleep quality improvement within 7 to 14 days, particularly reports of more vivid dreams (consistent with REM augmentation) Noticeable skin-thickness and nail-growth changes within 4 to 6 weeks Hunger increase that was manageable rather than uncontrollable The Moderate-Responder Cluster (roughly 55 percent of reports): IGF-1 increase of 20 to 59 percent Lean mass gains of 0.5 to 2 kg over 12 weeks Moderate sleep improvement Hunger increase rated moderate to significant The Low/Non-Responder Cluster (roughly 23 percent of reports): IGF-1 increase below 20 percent or no measurable change No meaningful body-composition shift Predominantly older users (median age 48), higher baseline BMI, poorer sleep, and inconsistent dosing timing These self-report proportions align reasonably well with the trial-level variance seen in the MK-677-024 dataset, where the coefficient of variation for IGF-1 response was 41 percent [1]

Liu, C., Zhang, Q., Zhou, H., Jin, L., Liu, C., Yang, M., Zhao, X., Ding, W., Xie, W., & Kong, H